Search results for "Disease management"

showing 10 items of 168 documents

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

2011

Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessmen…

OncologySorafenibLiver CirrhosisNiacinamidemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.drug_classPyridinesAntineoplastic AgentsGastroenterologyTyrosine-kinase inhibitorsystemic therapyliver cancerLiver diseaseInternal medicinemedicineHumansPharmacology (medical)treatmentbusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsDisease Managementhepatocellular carcinomamedicine.diseasehepatocellular carcinoma sorafenb cirrhosisdigestive system diseasesOncologyTolerabilityHepatocellular carcinomasorafenibLiver functionLiver cancerbusinessmanagementmedicine.drugcirrhosi
researchProduct

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

2018

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Oncologymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentMilan criteriaLiver transplantation03 medical and health sciences0302 clinical medicineResectable Hepatocellular CarcinomaHepatocellular carcinomaliver transplantation radiofrequenza ablation contrast enhanced Ultrasound antiangiogenetic drugs immunotherapyInternal medicinemedicineHumansEarly Hepatocellular CarcinomaSocieties MedicalHepatologybusiness.industryLiver NeoplasmsGastroenterologyDisease ManagementCancermedicine.diseaseBCLC Stage3. Good healthEurope030220 oncology & carcinogenesisHepatocellular carcinomaPractice Guidelines as Topic030211 gastroenterology & hepatologyLiver cancerbusinessJournal of Hepatology
researchProduct

The use of neural networks in identifying risk factors for lymph node metastasis and recommending management of t1b esophageal cancer.

2012

The objective of this study was to establish a prediction model of lymph node status in T1b esophageal carcinoma and define the best squamous and adenocarcinoma predictors. The literature lacks a satisfactory level of evidence of T1b esophageal cancer management. We performed an analysis pooling the effects of outcomes of 2098 patients enrolled into 37 retrospective studies using “neural networks” as data mining techniques. The percentages for lymph node, lymphatic (L1), and vascular (V1) invasion in Sm1 esophageal cancers were 24, 46, and 20 per cent, respectively. The same parameters apply to Sm2 with 34, 63, and 38 per cent as opposed to Sm3 with 51, 69, and 47 per cent. The respective …

Oncologymedicine.medical_specialtyEsophageal NeoplasmsLymph node metastasisAdenocarcinomaDiagnosis DifferentialText miningRisk FactorsInternal medicinemedicineCarcinomaHumansLymph nodeNeoplasm Stagingbusiness.industryDisease ManagementRetrospective cohort studyGeneral MedicineEsophageal cancermedicine.diseasemedicine.anatomical_structureLymphatic systemLymphatic MetastasisCarcinoma Squamous CellAdenocarcinomaNeural Networks ComputerbusinessThe American surgeon
researchProduct

Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib

2020

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by neoplastic transformation of pluripotent cells due to a typical cytogenetic and molecular mutation known as Philadelphia (Ph) chromosome. In 2001, the introduction of the tyrosine kinasis inhibitor (TKI) imatinib as a therapeutic strategy for CML with PH chromosome mutation represented an important step towards treatment of these patients, and nowadays, this drug represents the gold therapeutic standard in this clinical setting. A second generation of TKIs (dasatinib, nilotinib, and bosutinib) showed an effective action in all patients with mutations resistant to imatinib. Ponatinib is a third-generation TKI an…

Oncologymedicine.medical_specialtyTyrosine kinase inhibitorReview030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansNeoplastic transformation030212 general & internal medicineProtein Kinase InhibitorsTyrosine kinase inhibitorsCardiotoxicitybusiness.industryPonatinibChronic myeloid leukemiaImidazolesDisease ManagementMyeloid leukemiaImatinibPyridazinesDasatinibCardio-oncologyEarly DiagnosisNilotinibchemistryCardiovascular DiseasesPonatinibPonatinib . Tyrosine kinase inhibitors . Chronic myeloid leukemia . Cardio-oncology . ReviewCardiology and Cardiovascular MedicinebusinessBosutinibFollow-Up Studiesmedicine.drug
researchProduct

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and …

2016

WOS: 000393031600001

PREDICTIONInternational CooperationPoolingInformation Storage and RetrievalDisease030204 cardiovascular system & hematologyGUIDELINESDoenças Cardio e Cérebro-vascularesLDL-Cholesterol0302 clinical medicineCardiovascular DiseaseMedicineData MiningCardiac and Cardiovascular Systems030212 general & internal medicineRegistriesDisease management (health)Cooperative BehaviorGENERAL-POPULATIONRISKFamilial hypercholesterolaemia ; LDL-Cholesterol ; Cardiovascular disease ; RegistryKardiologiCONSENSUS PANELDelivery of Health Care IntegratedGeneral MedicineOrvostudományokCardiovascular diseasePREVALENCE3. Good healthTreatment OutcomeCARDIOVASCULAR-DISEASEResearch DesignFamilial hypercholesterolaemiaCardiology and Cardiovascular MedicineRegistrymedicine.medical_specialtyBest practiceKlinikai orvostudományokAccess to InformationHyperlipoproteinemia Type II03 medical and health sciencesEUROPEAN ATHEROSCLEROSIS SOCIETYInternal MedicineHumansOrganizational ObjectivesBespokeStudy DesignGUIDANCEbusiness.industryPublic healthStudy designProfessional Practice GapsData sharingClinical trialCardiovascular System & Hematology3121 General medicine internal medicine and other clinical medicineFamily medicineFamilial hypercholesterolaemia; LDL-Cholesterol; Cardiovascular disease; Registry; Study design; Familial Hypercholesterolaemia Studies CollaborationFamilial Hypercholesterolaemia Studies CollaborationFamilial HypercholesterolaemiaINDIVIDUAL PARTICIPANT DATAbusiness
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct

Clinical disorders responsible for plasma hyperviscosity and skin complications

2017

In this brief review, we have examined some clinical disorders which are associated to an altered hemorheological profile and at times accompanied by skin ulcers. This skin condition may be, in fact, observed in patients with primary plasma hyperviscosity such as multiple myeloma, Waldenstrom macroglobulinemia, cryoglobulinemia, cryofibrinogenemia, dysfibrinogenemia and connective tissue diseases. It must be underlined that the altered hemorheological pattern is not the only responsible for this skin complication but, as it worsens the microcirculatory flow, it contributes to determine the occurrence of the skin ulcers.

Pathologymedicine.medical_specialtyParaproteinemiasCryofibrinogenemiaHyperviscosityConnective tissuePlasma hyperviscosity030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesWhole-blood viscositySkin UlcerInternal MedicinemedicineHumansDysfibrinogenemiaConnective Tissue DiseasesMultiple myeloma030203 arthritis & rheumatologyintegumentary systembusiness.industryMicrocirculationDisease ManagementWaldenstrom macroglobulinemiaSyndromeBlood Viscositymedicine.diseaseCryoglobulinemiaDermatologymedicine.anatomical_structureCryoglobulinemiaWaldenstrom MacroglobulinemiaMultiple MyelomaComplicationbusinessEuropean Journal of Internal Medicine
researchProduct

Clinical course and management of acute and chronic viral hepatitis during pregnancy.

2014

Summary Pregnancy is a para-physiologic condition, which usually evolves without any complications in the majority of women, even if in some circumstances moderate or severe clinical problems can also occur. Among complications occurring during the second and the third trimester very important are those considered as concurrent to pregnancy such as hyperemesis gravidarum, intrahepatic cholestasis of pregnancy, HELLP syndrome and acute fatty liver of pregnancy. The liver diseases concurrent to pregnancy typically occur at specific times during the gestation and they may lead to significant maternal and foetal morbidity and mortality. Commonly, delivery of the foetus, even preterm, usually te…

Pediatricsmedicine.medical_specialtySettore MED/09 - Medicina InternaHepatitis Viral HumanHELLP syndromeAutoimmune hepatitisAcute fatty liver of pregnancyLiver diseaseHyperemesis gravidarumVirologyMedicineHumansPregnancy Complications InfectiousPregnancyanti-viral therapyHepatologybusiness.industryDisease Managementanti-viral therapy; liver disease; liver transplant; pregnancymedicine.diseaseLiver Transplantationliver transplantInfectious DiseasesImmunologyAcute DiseaseChronic DiseaseFemalepregnancybusinessViral hepatitisliver diseaseCholestasis of pregnancy
researchProduct

Chronic Spontaneous Urticaria and Type 1 Diabetes Mellitus—Does Quality of Life Impairment Always Reflect Health Danger?

2020

Background and aims: Chronic spontaneous urticaria (CSU) and diabetes mellitus type 1 (T1DM) may compromise the quality of life (QoL). We decided to compare the QoL of T1DM patients to those suffering from CSU. Materials and methods: Sixty-six patients with well-controlled T1DM (male 52%) in the mean age of (SD) 36.3 (11.09) years and 51 patients with CSU (male 33%) in the mean age of (SD) 35.8 (8.53) years were enrolled in this observational study. All the participants completed a Short-Form 36 (SF-36) QoL. Results: The QoL related to social functioning was significantly worse among CSU patients. There were differences related to gender found in the group of patients with T1DM&mdash

Pediatricsmedicine.medical_specialtyendocrine system diseaseslcsh:Medicine030209 endocrinology & metabolismchronic urticaria; diabetes; quality of lifeArticlechronic urticaria030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeDiabetes mellitusMedicineDisease management (health)Social functioningType 1 diabetesdiabetesbusiness.industrylcsh:Rnutritional and metabolic diseasesMean ageGeneral Medicinemedicine.diseasehumanitiesquality of lifeMarital statusObservational studybusinessJournal of Clinical Medicine
researchProduct

Editorial: Management of Elevated Heart Rate in Essential Hypertension: Pathophysiological Insights and Therapeutic Approach.

2017

Pharmacologybusiness.industryPhysical activityPhysical activityDisease ManagementBlood PressureBioinformaticsEssential hypertensionmedicine.diseasePathophysiologyElevated heart rateTherapeutic approachHeart RateDrug DiscoveryMedicineAnimalsHumansEssential HypertensionbusinessCurrent pharmaceutical design
researchProduct